PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known			
Application Number	10/029,206		
Filing Date	December 21, 2001		
First Named Inventor	Khan et al.		
Group Art Unit	1651		
Examiner Name	J. Witz		
Attorney Docket Number	2183-5222US	J	

•	(use as many	sneets as	necessary)
61		- 6	

U.S. PATENT DOCUMENTS Name of Patentee or Applicant of					
Examiner Initials *	Cits No. ¹	Number - Kind Code ² (If known)	Publication Date MM-DD-YYYY	Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JW		US-6,727,227	04-27-2004	Khavinson	
		US-			
		US-			
	1.	US-			
		US-			
	T	US-			

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	I.e	
JW		WO 01/29067	04-28-2001	Obschestvo S Ogranichennoi Otvetstvennostiju "Klinika Instituta Bioregulyatsii I Gerontologii"			
				 			
	l						

Examiner			Date	
Signature	/Jean Witz/	(07/21/2006)	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and rademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 223121450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not considered, Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

Inter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known 10/029,206

December 21, 2001

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

First Named Inventor Group Art Unit Examiner Name

Application Number

Filing Date

1651 J. Witz Attorney Docket Number 2183-5222US

Khan et al.

(use as many sheets as necessary) Sheet of

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item T² Cite Examiner (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volumeissue number(s), publisher, No.1 Initials * city and/or country where published. KHAVINSON et al., "Mechanisms Underlying Geroprotective Effects of Peptides," Bulletin of Experimental Biology and JW. Medicine, January 2002, pp. 1-5, Vol. 133, No. 1. KHAVINSON et al., "Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell," Bulletin of Experimental Biology and Medicine, May 2004, pp. 503-506, Vol. 137, No. 5. MOROZOV et al., "Natural and Synthetic Thymic Peptides as Therapeutics for Immune Dysfunction," Int. J. Immunopharmac. 1997, pp. 501-505, Vol. 19, No. 9/10. KHAVINSON et al., "Inductive Activity of Retinal Peptides," Bulletin of Experimental Biology and Medicine, November 2002, pp. 482-484, Vol. 134, No. 5. KHAVINSON et al., "Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects," Bulletin of Experimental Biology and Medicine, January 2004, pp. 78-81, Vol. 137, No. 1. KHAVINSON et al., "Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People," Bulletin of Experimental Biology and Medicine, October 2002, pp. 389-392, Vol. 134, No. 4. KHAVINSON et al., "Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells," Bulletin of Experimental Biology and Medicine, June 2003, pp. 590-592, Vol. 135, No. 6. IVANOV et al., "Hemoglobin as a Source of Endogenous Bioactive Peptides: The Concept of TissueSpecific Peptide Pool," Biopolymers, 1997, pp. 171-188, Vol. 39. JW KHAVINSON et al, Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland.

Examiner	/Jean Witz/ (07/21/2006)	Date Considered	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformanced not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form isestimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Chee, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 223131450.



Unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.